Kyverna Therapeutics, Inc.
KYTX
$7.66
-$0.19-2.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 10.99% | -0.84% | -6.65% | -46.10% | -67.22% |
| Total Depreciation and Amortization | -29.94% | -34.64% | -25.63% | -2.83% | 3.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 126.23% | 1,386.98% | 59.73% | 548.39% | -44.41% |
| Change in Net Operating Assets | -146.98% | 5,000.00% | -268.53% | 86.64% | -18.82% |
| Cash from Operations | 7.39% | 9.54% | -57.59% | -32.16% | -75.96% |
| Capital Expenditure | -- | 100.19% | 98.04% | 99.61% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -999.98% | -158.10% | 2,790.62% | 143.61% | 104.56% |
| Cash from Investing | -999.98% | -159.16% | 3,236.83% | 142.94% | 104.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 74.78% | 65.59% | 50.41% | -11.02% | -47.62% |
| Issuance of Common Stock | 8,000.00% | 363,153.13% | 1,734.44% | -100.00% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 9.21% | -- | -- | 17.24% | 97.43% |
| Cash from Financing | 75.60% | 65,561.86% | 1,078.95% | -14.06% | -100.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -131.19% | 1,216.58% | 28.51% | 96.30% | -120.96% |